BeOne Medicines (BEIGF) Minority Interest (2017 - 2020)

BeOne Medicines (BEIGF) has reported Minority Interest for 4 consecutive years, with $9.0 million the latest figure, recorded in Q3 2020.

• On a quarterly basis, Minority Interest fell 42.76% year-over-year to $9.0 million in Q3 2020; TTM through Sep 2020 was $9.0 million, a 42.76% decrease from a year earlier, with the FY2019 full-year figure at $16.2 million, up 11.8% from the prior year.
• Minority Interest was $9.0 million for Q3 2020 at BeOne Medicines, down from $10.2 million in the prior quarter.
• Over five years, Minority Interest peaked at $17.4 million in Q2 2019 and troughed at $9.0 million in Q3 2020.
• A 4-year average of $14.0 million and a median of $14.4 million in 2017 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest rose 29.07% in 2019 and slumped 42.76% in 2020, its largest moves.
• Over 4 years, Minority Interest stood at $14.4 million in 2017, then increased by 0.16% to $14.4 million in 2018, then gained by 11.8% to $16.2 million in 2019, then slumped by 44.15% to $9.0 million in 2020.
• The last three Minority Interest figures came in at $9.0 million (Q3 2020), $10.2 million (Q2 2020), and $14.8 million (Q1 2020), per Business Quant data.